- Home
- HYPR vs RFL Comparison
HYPR vs RFL Comparison
Compare HYPR & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYPR | RFL |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.9M | 61.1M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HYPR | RFL |
|---|---|---|
| Price | $1.14 | $1.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.28 | N/A |
| AVG Volume (30 Days) | ★ 293.1K | 88.6K |
| Earning Date | 04-20-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.68 | ★ 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,890,000.00 | $917,000.00 |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $34.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 16.84 | ★ 43.96 |
| 52 Week Low | $0.53 | $1.12 |
| 52 Week High | $2.22 | $3.19 |
Technical Indicators
Market Signals| Indicator | HYPR | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 67.39 |
| Support Level | $1.04 | $1.41 |
| Resistance Level | $1.19 | $1.63 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 65.85 | 77.50 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.